News of the Navax Influenza paper published in the journal  Scientific Reports

On September 8, 2023, doctors from the Vietnam National Children’s Hospital, in collaboration with the research team of ANABIO R&D Co. Ltd, continued to announce the results of a study on the effectiveness of nasal-spraying containing Bacillus spore probiotics (LiveSpo Navax) in the Scientific Reports – Nature journal, entitled “Efficient symptomatic treatment and viral load reduction for children with influenza virus infection by nasal-spraying Bacillus spore probiotics”.

Scientific Reports, belonging to the Nature system, is a famous medical journal in the world. The second replication of this remarkable study in Scientific Reports – Nature proves its scientific rigor and quality, rather than being mere luck.

LiveSpo Navax is an ear, nose, and throat cleaning solution containing more than 5 billion spore probiotics of Bacillus subtilis and Bacillus clausii, along with physiological saline solution (NaCl 0.9%) in a sufficient 5 mL volume. This product is dedicated to cleaning the ear, nose, and throat; it helps prevent and reduce the risk of ear, nose, and throat infections while also supplementing spore probiotics to protect and recover the nasal mucosa.

This study is a double-blind, randomized, and controlled clinical trial, the first of its kind in the world, demonstrating the safety and effectiveness of nasal-spraying Bacillus liquid-form probiotics (LiveSpo Navax) in the treatment of acute respiratory tract infections (ARTIs) in children infected with the influenza virus. The research results show that LiveSpo Navax, when administered directly into the nasal cavity, rapidly reduces the symptoms of ARTIs, significantly shortening the recovery time by more than 2 days. Furthermore, the combination of LiveSpo Navax and standard therapy enhances treatment effectiveness by 58% in the treatment of all acute respiratory tract infection (ARTI) symptoms due to influenza virus.

Especially, LiveSpo Navax significantly inhibits the multiplication of the influenza virus (by 417-fold), reduces bacterial co-infection concentrations such as S. pneumoniae, H. influenzae (by 1152-fold), and enhances immune regulation, reducing the risk of the ‘cytokine storm’ by effectively reducing pro-inflammatory cytokines like IL-6, IL-8, and TNF-α by 1.1 – 53,9-fold. This was 26-fold (for viral loads), 65-fold (for bacterial co-infection concentrations), 1.1 – 9.5-fold (for cytokine levels), and 1.3-fold (for IgA levels) more effective than the control standard-of-care group. Through two publications on the effects of Bacillus spore probiotics originating from Vietnam, Dr. Nguyen Hoa Anh – Director of ANABIO R&D Co. Ltd., reaffirms that nasal spray is not only effective in capturing and inactivating one type of virus but can also assist in the treatment of respiratory tract infections in general, including emerging viruses such as RSV, influenza, adenovirus, SARS-CoV-2, etc. This is because the mechanism of interaction between Bacillus spores with the nasal mucosal immune system, virus, and bacteria is non-specific. Nasal-spraying containing Bacillus spore probiotics can enhance the protective barrier, compete with viruses and bacteria on the nasal mucosa surface, and boost immune responses. LiveSpo Navax has the advantage of being simple to use, cost-effective, and enhancing the effectiveness of vaccines and drugs in preventing and treating viral infections, as well as reducing the cost and duration of treatment with antibiotics in cases of bacterial co-infection. These factors make nasal-spraying LiveSpo Navax an ideal solution for developing countries that have limited medical resources and face challenges with hospital overload, and reduce dependence on antibiotics. In the near future, we will conduct further clinical trials to evaluate the preventive effects of nasal-spraying Bacillus spores (LiveSpo Navax) on respiratory tract infections in children during the transitional season, especially when there is a high prevalence of viral and bacterial pathogens.

Meet and share products at Thai Nguyen General Hospital

On September 15, 2022, the ETC department and ANABIO R&D had a meeting to share at the Department of Pediatrics – Thai Nguyen Central General Hospital about a set of 03 products: LiveSpo Navax, LiveSpo Dia30 and LiveSpo Pregmon

Pictures at the sharing session

At the meeting, the research team of ANABIO R&D brought expertise and basic information about LiveSpo Navax, LiveSpo Dia30 and LiveSpo Pregmon products as well as answered common problems encountered during the adjustment process. treatment, used when combining products. This helps to strengthen and create trust for the team of doctors and customers during use.

Research on spore probiotics LiveSpo Navax has been published in prestigious international scientific journal

On July 20th, 2022, the research article regarding nasal-spraying spore probiotics LiveSpo Navax entitled “Nasal-spraying Bacillus spores as an effective symptomatic treatment for children with acute respiratory syncytial virus infection” was published in Scientific Reports-Nature, the prestigious international scientific journal. The study was conducted in collaboration between LiveSpo Pharma Co. Ltd., and researchers at Vietnam National Children’s Hospital.

Scientific Reports, belonging to Nature system, is famous medical journal in the world. By the publication on effects of spore probiotics originating from Vietnam, Dr. Nguyen Hoa Anh – Director of ANABIO R&D Co. Ltd., expects to be able to contribute to the field of science and public health care, especially children.

The study was published in the journal Scientific Reports

The research group conducted the clinical trial of nasal-spraying spore probiotics LiveSpo Navax on RSV infected children. LiveSpo Navax is ear, nose and throat cleaning solution containing more than 5 billion of spore probiotics Bacillus subtilis and Bacillus clausii and physiological saline solution (NaCl 0.9%) in sufficient 5 mL. Product is dedicated for cleaning of ear, nose and throat; help preventing and reducing the risk of ear, nose and throat infections; supplementing of spore probiotics to protect and recover the nasal mucosa.

The study demonstrates that LiveSpo Navax treatment resulted in 1-day faster recovery time and 10-50% better efficacy in relieving typical symptoms of acute respiratory tract infections (ARTIs) in comparison to control group. At day 3 of treatment, levels of RSV load and pro-inflammatory cytokines in nasopharyngeal samples of patients using LiveSpo Navax were remarkably reduced by 630 folds and 2.7-12.7 folds, respectively, which was 53-fold and 1.8 to 3.6-fold more effective than those in standard of care treatment.

Spraying LiveSpo Navax directly in to nasal cavity helps reducing the symptoms of ARTIs rapidly. In combination between LiveSpo Navax and standard therapy, the recovery time is shortened by 1 day (17%) with 10-50% more effectiveness in relieving typical symptom of ARTIs than physiological saline solution. Most of patients having positive co-infection bacteria in Navax group became negative after 3 days of treatment, while low reduction and even increment in co-infection bacteria were detected in most of patients in standard of care treatment.

LiveSpo Navax products used in research

Dr, Nguyen Hoa Anh, a member of research group and Director of ANABIO R&D, said: The mechanism of interaction between spore probiotic Bacillus in LiveSpo Navax and virus and immune system of nasal mucosa is based on non-specific interaction. “Our discovery suggests that LiveSpo Navax may useful for against the recent novel respiratory viral variants such as nCoV. This novel supportive treatment method using probiotics has the advantage of simplicity of use, low cost, effectible and viral infected prevention. It can support the developing countries with limited health resources”.

Attending the International Microbiology Conference 2022

From June 9-13, 2022, the 2022 International Microbiology Conference took place in Washington DC. The conference is organized by the American Society for Microbiology Microbe (ASM Microbe 2022), which is the largest and most prestigious organization in the field of microbiology in the world.

The conference is a forum for scientists around the world to exchange discoveries, creativity and research collaboration in different fields of microbiology.

Participating in the Conference, there were many useful and quality scientific reports from research organizations from all over the world, including the participation of researchers from the Center for Cell Research. Probiotic bacteria, ANABIO R&D Co., Ltd.

Dr. Nguyen Hoa Anh, presented the report at the Conference

At the Conference, Dr. Nguyen Hoa Anh and CN. Bui Thi Huyen – ANABIO R&D has had 03 reports related to the clinical trial results of the probiotic product LiveSpo Navax conducted at the National Children’s Hospital.

Report of Dr. Nguyen Hoa Anh at the Conference

LiveSpo Navax, containing 5 billion spores of the beneficial bacteria Bacillus subtilis and Bacillus clausii in nasal spray form, has a significant effect in shortening the duration of treatment of respiratory infections in children infected with respiratory syncytial virus (RSV) and flu. Research shows that LiveSpo NAVAX reduces the concentration of these two viruses about 50-60 times more effectively than physiological saline. Besides, LiveSpo NAVAX also works to reduce “cytokine storm” clearly, has anti-inflammatory and nasal congestion effect.

CN. Bui Thi Huyen presented a report at the Conference

Regarding beneficial bacteria for gastrointestinal diseases, ANABIO R&D also had 01 report on heat stability, acid stability, time stability and safety of LiveSpo Clausy product, which has a significant supportive effect in reducing tangles. Digestive disorders when taking antibiotics.

Report on LiveSpo Clausy at the Conference

Research shows that LiveSpo Clausy is very safe, has stable quality during storage, does not reduce its effect when it passes through the stomach, when it enters the intestines, it promotes the effect of improving the intestinal microflora, bringing the intestinal microflora to the balance ratio of 80:20 between good bacteria and bad bacteria after only 28 days of use.

The conference ended successfully after 5 days, leaving many good impressions for the scientists who attended the conference about the professionalism in the organization and the scientific quality of the reports. Through the conference, ANABIO R&D was highly appreciated by the scientific community for its product quality as well as contributing to improving the reputation of Vietnamese brands in the field of probiotics in the world.

Establishment of Spore Probiotics Research Center

On May 18, 2022, LiveSpo Global JSC. held a press conference to establish the Spobiotic Research Center with the hope that it will be a source of motivation for more scientists to pay attention to and develop probiotic spores as a solution to control bacteria. to an ANTIbiotic-free FUTURE. 

Attending the ceremony were professors, doctors from agencies, hospitals, universities as well as business partners. This proves that research has received a lot of attention from scientists, as well as businesses, in the application of beneficial bacteria spores in real life.

Photos of guests attending the Center’s founding ceremony

Speaking at the ceremony, Dr. Nguyen Hoa Anh, Director of the Center said, “Currently, the situation of people using “antibiotics” unnecessarily, for a long time causing drug resistance, also known as antibiotic resistance, is extremely common. The World Health Organization (WHO) has raised it, but there is not really an effective solution to replace antibiotics.”

Dr. Nguyen Hoa Anh speaks at the ceremony

Theoretically, in addition to antibiotics, beneficial bacteria can be used to inhibit and kill pathogenic bacteria. In order to gradually replace antibiotics, in addition to digestive diseases, beneficial bacteria spores need to be studied to expand their functions, new applications, fast and clear effects. In addition, probiotic spores need to have the opportunity to perform clinical trials not only for gastrointestinal diseases, but also for respiratory infections, ear infections, dermatitis, gynecological inflammations…

In order to be more accessible to users, in-depth research on probiotic spores, with the goal of providing a great user experience, is extremely necessary. Since then, realizing the opportunity to gradually replace antibiotics.

Representatives of the Board of Directors cut the ribbon at the ceremony

The Center for Research on Probiotic Spores was established by Dr. Nguyen Hoa Anh with many modern machines and equipment, in order to serve in-depth research on beneficial bacteria spores by microbiological, biophysical, biochemical, molecular and cellular techniques. The establishment of the Center has realized the dream of Dr. Nguyen Hoa Anh after 15 years of studying, researching and teaching at TOHOKU University, Japan. Returning to Vietnam in 2010, Dr. Nguyen Hoa Anh brings with him a wish to contribute to “construction of his homeland, and hopes that in the future Vietnam will also be recognized as one of the “countries that contribute to inventions” of advanced technology for mankind.

LiveSpo Global is the sponsor for the construction and maintenance of the Probiotic Spore Research Center. LiveSpo is a highly capable brand with a value chain from R&D, clinical trials, production to distribution of probiotic spore products. With breakthrough production technology, LiveSpo’s products are clearly effective and absolutely safe for babies, ready to serve the mission FOR A ANTIbiotic-free FUTURE.

Hosted By Wordpress Clusters